What is the primary purpose of the iPLEDGE program?

The primary purpose of the iPLEDGE program is to prevent pregnancy during isotretinoin use. Isotretinoin, a powerful medication used for treating severe acne, has a high risk of causing birth defects if taken during pregnancy. The iPLEDGE program is designed to ensure that patients are aware of these risks and take necessary precautions to avoid pregnancy while receiving treatment. It includes requirements for patient registration, counseling, and regular pregnancy testing, all aimed at preventing fetal exposure to the medication.

The other options do not align with the objectives of the program. While medication affordability and promoting generic alternatives are important healthcare issues, they are not the focus of iPLEDGE. Additionally, the program does not address drug interactions, which are managed through different regulatory and clinical processes. Thus, the emphasis of iPLEDGE remains on reproductive safety concerning isotretinoin usage.